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Bio-Medical
Benchtop Detection of  Proteins 
This process is relatively rapid and simple. 
John H. Glenn Research Center, Cleveland, Ohio
A process, and a benchtop-scale appara-
tus for implementing the process, have
been developed to detect proteins associ-
ated with specific microbes in water. The
process and apparatus may also be useful
for detection of proteins in other, more
complex liquids. There may be numerous
potential applications, including monitor-
ing lakes and streams for contamination,
testing of blood and other bodily fluids in
medical laboratories, and testing for micro-
bial contamination of liquids in restaurants
and industrial food-processing facilities. A
sample can be prepared and analyzed by
use of this process and apparatus within
minutes, whereas an equivalent analysis
performed by use of other processes and
equipment can often take hours to days.
The process begins with the conjugation
of near-infrared-fluorescent dyes to anti-
bodies that are specific to a particular  pro-
tein. Initially, the research has focused on
using near-infrared dyes to detect antigens
or associated proteins in solution, which
has proven successful vs. microbial cells,
and streamlining the technique in use for
surface protein detection on microbes
would theoretically render similar results.
However, it is noted that additional work is
needed to transition protein-based tech-
niques to microbial cell detection.  Conse-
quently, multiple such dye/antibody pairs
could be prepared to enable detection of
multiple selected microbial species, using a
different dye for each species. When ex-
cited by near-infrared light of a suitable
wavelength, each dye fluoresces at a
unique longer wavelength that differs from
those of the other dyes, enabling discrimi-
nation among the various species.
In initial tests, the dye/antibody pairs
are mixed into a solution suspected of
containing the selected  proteins, causing
the binding of the dye/antibody pairs to
such  suspect proteins that may be pres-
ent. The solution is then run through a
microcentrifuge that includes a mem-
brane that acts as a filter in that it retains
the dye/antibody/protein complexes
while allowing any remaining unbound
dye/antibody pairs to flow away.
The retained dye/antibody/protein
complexes are transferred to a cuvette,
wherein they are irradiated with light
from a miniature near-infrared laser deliv-
ered via a fiber-optic cable. The resulting
fluorescence from the dye(s) is measured
by use of a miniature spectrometer, the
output of which is digitized, then analyzed
by laptop computer. The software run-
ning in the computer identifies the pro-
tein species by the wavelengths of their
spectral peaks and determines the
amounts of the proteins, and thus, one
day, microbes of the various species from
the intensities of the peaks. The above-
mentioned removal of the unbound
dye/antibody pairs during centrifugation
prevents false positive readings. The
process proves successful in detecting pro-
teins in solution and thus can now be em-
ployed for use in microbe detection.
This work was done by Maximilian C.
Scardelletti and Vanessa Varaljay of Glenn
Research Center. 
Inquiries concerning rights for the commer-
cial use of this invention should be addressed
to NASA Glenn Research Center, Innovative
Partnerships Office, Attn: Steve Fedor, Mail
Stop 4–8, 21000 Brookpark Road, Cleveland,
Ohio 44135. Refer to LEW-18148-1.
Recombinant Collagenlike Proteins
These proteins can be tailored to have specific biological properties.
Lyndon B. Johnson Space Center, Houston, Texas
A group of collagenlike recombinant
proteins containing high densities of bi-
ologically active sites has been invented.
The method used to express these pro-
teins is similar to a method of expressing
recombinant procollagens and colla-
gens described in U. S. Patent 5,593,859,
“Synthesis of human procollagens and
collagens in recombinant DNA systems.”
Customized collagenous proteins are
needed for biomedical applications. In
particular, fibrillar collagens are attrac-
tive for production of matrices needed
for tissue engineering and drug delivery.
Prior to this invention, there was no way
of producing customized collagenous
proteins for these and other applica-
tions. Heretofore, collagenous proteins
have been produced by use of such bio-
logical systems as yeasts, bacteria, and
transgenic animals and plants. These
products are normal collagens that can
also be extracted from such sources as
tendons, bones, and hides. These prod-
ucts cannot be made to consist only of
biologically active, specific amino acid
sequences that may be needed for spe-
cific applications.
Prior to this invention, it had been es-
tablished that fibrillar collagens consist
of domains that are responsible for such
processes as interaction with cells, bind-
ing of growth factors, and interaction
with a number of structural proteins
present in the extracellular matrix. A
normal collagen consists of a sequence
of domains that can be represented by a
corresponding sequence of labels, e.g.,
D1D2D3D4. A collagenlike protein of
the present invention contains regions
of collagen II that contain multiples of a
single domain (e.g., D1D1D1D1 or
D4D4D4D4) chosen for its specific bio-
logical activity. By virtue of the multiplic-
ity of the chosen domain, the density of
sites having that specific biological activ-
ity is greater than it is in a normal colla-
gen. A collagenlike protein according to
this invention can thus be made to have
properties that are necessary for tissue
engineering.
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